Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease

Real‐world use of cardioprotective glucose‐lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019

“…Optimal medical treatment including antiplatelet drugs, anti‐hypertensive drugs and cardioprotective GLDs is important for the prevention of recurrent CVD events in patients with T2DM and CVD, 32 however, the proportion of patients with T2DM and CVD in optimal medical treatment remains low 33 . The low use of cardioprotective GLDs seems to be an important part of this undertreatment as documented in the present study and others 20,23,34 .…”

Potential unrealized mortality benefit of glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transport‐2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program

“…However, a majority of eligible patients remain untreated with these medications 9 . Our findings of low prevalent use of GLP‐1RAs and SGLT2is despite trial eligibility are consistent with prior reports 21–24 . Low utilization of GLP‐1RAs and SGLT2is, despite large‐scale cardiovascular outcomes trials showing efficacy published as early as 2015, may be related to unfamiliarity with the drugs, a lack of knowledge regarding their cardiovascular benefits, hesitancy to prescribe additional medications, reluctance to overstep traditional specialist prescriber roles for diabetes therapy, and the cost of therapy 24–26 .…”

Cost‐effectiveness analysis of empagliflozin versus sitagliptin as second‐line therapy for treatment in patients with type 2 diabetes in the United States

“…Despite ADA treatment guidelines, 3 the use of DPP‐4is (12.5% in a large US cohort from 2016 to 2018) 7 with no demonstrated CVD benefit continues to be higher than SGLT‐2is and GLP‐1RAs (9.0% and 7.9%, respectively), 7 agents with well‐documented CV benefits. Another study showed that drug choice in US patients with T2D did not vary by presence of CVD 8 .…”